MELI

Summary

Sell MELI at ~$1,784–1,786. This is an actively-managed call, not a passive default: the stock sits on a critical support confluence (Bollinger lower band ~1,760 and 50-day SMA ~1,767) with a broken short-term technical picture (MACD bearish crossover, price below 200 SMA ~1,877, RSI falling to 45). Fundamentals remain exceptional (record revenue $10.17B +49.8% YoY, $3.66B quarterly operating cash flow, 27.5% ROE), but the near-term setup argues for reducing exposure rather than holding through a knife's-edge support zone. Position sizing: existing holders should trim/reduce rather than maintain full core positions; no new longs at current levels. Key risk levels: a decisive close below 1,760 on above-average volume invalidates the support thesis and confirms the downside path (next downside target ~1,583–1,650); a reclaim of the 10 EMA (~1,840) and then the 200 SMA (~1,877) would reassert the bull case and warrant reconsideration. Given elevated ATR (64.43), use stops 1.5–2x ATR (~97–129 points) below entry. Time horizon: 5 trading days for the alpha call, with the decisive fundamental catalyst being the next earnings report and credit-quality metrics (provision rate vs. loan growth) in ~2–3 months.

The case

The strongest point in the bear case is the credit-cycle red flag: provisions for doubtful accounts grew 85% YoY to $1.28B, faster than the 73% loan-book growth to $11.4B — meaning the provision *rate* is rising, a genuine early-warning signal. Total debt up 47% to $13.18B (debt-to-equity 168.6%) and a thin current ratio of 1.12 add leverage risk. The bull's rebuttal is the cash-generation reality: $3.66B quarterly operating cash flow is ~7.8x net income of $466M, and the TTM-FCF discrepancy is a definitional artifact (netting credit originations), not a liquidity crisis. The margin argument also carries a seasonal flaw (Q2 vs. Q4 comparison is apples-to-oranges for a holiday-heavy e-commerce business).

Weighing these, the near-term edge tilts to the downside. The bull's growth story (30 straight quarters of >30% growth, JPM target hike to $2,150, Burry accumulation, 31.5x forward earnings with PEG 1.31) argues against panic-selling into a 30% drawdown at support. But the bear's credit deterioration and broken technicals (price below 200 SMA, MACD bearish crossover, put/call 1.56 signaling defensive hedging) argue against holding through a support decision point. The stock fell 8% on record earnings — the market is explicitly demanding margin proof before re-rating, and until that proof arrives the path of least resistance is lower.

Neutral Holds on high-beta names have historically left significant directional moves uncaptured, and MELI is genuinely range-bound at a support decision point with a 2-3 month catalyst gap. The JPM target hike and Burry accumulation are real, recent catalysts, but they are not enough to offset deteriorating credit metrics and broken technicals over the 5-day window.

Our analysis reflects a slight tilt toward the downside (risk/reward is unfavorable if support breaks, with the next downside target ~1,583–1,650). The next 5 trading days are dominated by technicals at a knife's-edge support zone, where the outcome is close to a coin flip but with a marginal negative skew from credit deterioration and defensive hedging. We are committing to Sell because the triggers are defined and the stance is active: reduce exposure now, with a decisive close below 1,760 confirming the downside path.

What would weaken it

• Exceptional fundamentals (record revenue $10.17B +49.8% YoY, $3.66B operating cash flow) could reassert the bull case
• Reclaim of 10 EMA (~1,840) and 200 SMA (~1,877) would invalidate the downside thesis
• JPM target hike to $2,150 and Burry accumulation are real recent catalysts